Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIIM study of Hizentra in adults with dermatomyositis
2023-508293-28-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Apr 2024
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Hizentra with Placebo (2 arms). Primary endpoint: Responder rate. Started Apr 2024; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2023-508293-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508293-28-00.